An independent committee is reviewing potential safety concerns related to the sick United Kingdom trial participant, which led to the trial pause.
"We could still have a vaccine by the end of this year, early next year", Soriot said at an event hosted by the Tortoise media group on Thursday, as quoted in a report by news agency ANI.
According to health industry news site Stat, which first reported the pausing of the trials, Mr Soriot also confirmed the clinical trial was halted once in July after a participant experienced neurological symptoms and was diagnosed with multiple sclerosis.
Russian Federation was the first country to release its vaccine - Sputnik-V, which has undergone two trials, with no serious side effects.
India will be producing 300 million doses of the vaccine.
"They will be considering all factors including the time from when they became vaccinated to when they fell ill", Associate Professor Wood said.
In a company statement, AstraZeneca has said that all trials of its COVID-19 vaccine would remain on hold until an independent committee completed its review of the safety data of the participant who developed a spinal inflammatory disorder occurred in the UK Phase 3 trial. If it's main because it was on this case - it was a extreme facet occasion - and due to this fact the trial was halted. "This is good clinical practice because safety is of the utmost, highest priority in any clinical trial".
Swaminathan mentioned, "We hope that issues will be capable of transfer on however once more it relies upon".
AFP reported Jeremy Farrar, the director the Wellcome Trust telling the BBC radio in an interview that there were often pauses in vaccine trials.
The trials of the Russian vaccine in Brazil will start in October.
Patrick Vallance, Britain's chief scientific adviser mentioned comparable occasions must be anticipated however progress on vaccines and therapeutics was optimistic total.
"Some will read out this year in terms of efficacy and safety", he told a Downing Street news conference.
Professor Senanayake said the size of the trial was a factor.